Biopharma companies funnel cash to defeat Calif. drug proposal

Drug companies have been funneling tens of millions of dollars into a war chest that will be used to campaign against a California initiative that would require manufacturers to extend discounts to low-income residents or face being kicked off the state's Medicaid formulary. Merck and GlaxoSmithKline have each anted up $8.54 million, with millions more coming from Amgen, Eli Lilly and Novartis. The money will also go to support an industry initiative that would create a voluntary discount program. Analysts say the companies are moving to protect millions in profits gained from the state's $4 billion Medicaid drug bill.

- read this article from The New York Times for more 

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.